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Abstract
Background: The risks/benefits balance of hormone replacement therapy is controversial. Information can influence
consumers' knowledge and behavior; research findings about hormone replacement therapy are uncertain and the messages
provided by the media are of poor quality and incomplete, preventing a fully informed decision making process.
We therefore felt that an explicit, rigorous and structured assessment of the information needs on this issue was urgent and we
opted for the organisation of a national consensus conference (CC) to assess the current status of the quality of information on
hormone replacement therapy (HRT) and re-visit recent research findings on its risks/benefits.
Methods: We chose a structured approach based on the traditional CC method combined with a structured preparatory work
supervised by an organising committee (OC) and a scientific board (SB). The OC and SB chose the members of the CC's jury
and appointed three multidisciplinary working groups (MWG) which were asked to review clinical issues and different aspects
of the quality of information. Before the CC, the three MWGs carried out: a literature review on the risk/benefit profile of HRT
and two surveys on the quality of information on lay press and booklets targeted to women. A population survey on women's
knowledge, attitude and practice was also carried out. The jury received the documents in advance, listened the presentations
during the two-day meeting of the CCs, met immediately after in a closed-door meeting and prepared the final document.
Participants were researchers, clinicians, journalists as well as consumers' representatives.
Results: Key messages in the CC's deliberation were: a) women need to be fully informed about the transient nature of
menopausal symptoms, about HRT risks and benefits and about the availability of non-pharmacological interventions; b) HRT is
not recommended to prevent menopausal symptoms; c) the term "HRT" is misleading and "post menopausal hormone therapy"
should be the preferred definition.
Conclusion: This CC led to the identification of specific information drawbacks. Women are exposed to messages that are
often partial, non evidence-based nor transparently developed. The structured and participative methodology of this CC allowed
a multidisciplinary perspective and a substantial lay people input.
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In Italy, as in other countries, opinions and views about
hormone replacement therapy (HRT) vary widely among
scientific societies, specialists, and general practitioners
[1].
At the beginning of the nineties, observational studies
suggested that HRT was effective for most symptoms and
diseases of menopausal women and its use was recom-
mended as the intervention was deemed to reduce cardio-
vascular and osteoporotic risks. However, HRT's
disadvantages emerged from two large randomized con-
trolled trials (RCTs) – the Heart estrogen-progestin
replacement study (HERS) [2] and the Women health ini-
tiative (WHI) [3] – that found no benefits for prevention
of cardiovascular diseases. Particularly, the WHI trial
found an increase in breast cancer incidence and in cardi-
ovascular events in healthy women. Later, The million
women study [4] showed an increase in breast cancer inci-
dence associated with the therapy. The publication of
these new findings, supported by large RCTs, led to differ-
ent interpretations among researchers, specialists (mainly
gynecologists and oncologists) and general practitioners.
The subsequent guidelines and recommendations
endorsed by Italian medical societies and healthcare insti-
tutions often disagreed. Not surprisingly, also patients
and consumers associations' documents, booklets and
brochures gave contradictory messages. In this context,
information on menopause was often incorrectly
reported: it is described as a disease, especially in newspa-
pers and TV programs, leading to the medicalisation of a
natural event in women's life. For all these reasons,
women are likely to receive unbalanced and incomplete
information from doctors, mass media and other sources
and confusion prevails on the pros and cons of taking hor-
mones for menopausal symptoms.
We therefore felt that an explicit, rigorous and structured
assessment of the information needs on this issue was
urgent and we opted for the organisation of a national
consensus conference (CC) aimed at assessing the corre-
spondence/dissonance between the state of art of scien-
tific research and the information that is conveyed to
women. Besides the traditional format of a CC – including
a two-day meeting with a jury listening to the reports of
expert witnesses and then issuing a set of recommenda-
tions – we set up a process, already tested in previous CCs
in Italy, whereby the two-day meeting comes at the end of
highly structured and intense preparatory activities which
are described in details below. The conference was enti-
tled "Informing women about hormone replacement
therapy" and it was organised by the Partecipasalute
project – coordinated by Istituto di Ricerche Farmacolog-
iche Mario Negri with the collaboration of Italian
Cochrane Centre and Zadig, scientific publishing com-
pany – and the National Guidelines System (SNLG) based
at the Istituto Superiore di Sanità. The conference took
place in Turin on 16 and 17 May 2008.
Methods
In April 2007 the organising committee (OC) identified a
scientific board (SB) to support the development of the
conference and, together with the SB, appointed a multi-
disciplinary jury. The OC and the SB, after discussing dif-
ferent aspects of the issue, defined the main questions to
which the CC jury was called to answer (table 1). Mem-
bers of the scientific board, the jury and the working
groups are listed in appendix 1. Ethics approval was not
necessary for CC.
Working groups
In order to weigh up the scientific data available on HRT
and to evaluate the information conveyed to women from
different sources, three working groups were appointed,
dealing with: scientific evidence available; information
published in newspapers and magazines; information
provided in booklets, brochures and websites specifically
targeted to women and focused on menopause. The first
group included two gynecologists, two general practition-
ers, one cardiologist and one endocrinologist. This work-
ing group assessed the scientific literature available on
HRT starting from guidelines published by public institu-
tions, then Cochrane reviews or meta-analysis, individual
primary studies directly assessing the impact of HRT on
women's health and, finally, observational studies or
statements made by experts. This latter source was consid-
ered only if the method to produce the documents was
described and potential conflicts of interests disclosed.
Table 1: Questions addressed by the consensus conference
1. What is the information about menopause and HRT that women would value most?
2. What is the average quality of the information available on this health issue? Which are the main risks for the general public and professionals 
associated with the dissemination of deceitful and unreliable information? How to improve the scientific quality of the information?
3. Which characteristics of the menopause can be linked to health problems?
4. Why should we prescribe HRT, which are the main objectives of the therapy, which women are eligible to receive it and what would be the 
duration of the treatment?
5. Which alternatives to HRT, especially non-pharmacological, need more information?
6. What are the priorities for future research?Page 2 of 8
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the press was composed of five journalists and one clini-
cian; the other group, dealing with booklets, brochures
and information material targeted to women was com-
posed of patients' associations representatives, researchers
and lay members of ethics committees. Two hundred and
twenty five articles published in the press from 2000 to
2007 and 78 documents targeted to women were
extracted from available sources (publisher's archives or
search engines in internet) and appraised using a stand-
ardized form dealing with graphic layout, editing, trans-
parency of information, contents related to menopause
and HRT. Specifically, the main items of the form were:
date of publication; title of the document; ownership of
the document or website; author; sponsorship; presence
of photos or tables; length of the document; type of infor-
mation conveyed; sources of information; how meno-
pause is described (as a disease, as a physiological phase);
how HRT is described: is it suggested to cure symptoms?
To prevent risks? Are HRT's risks described? Is the length
of therapy reported? Are treatments alternative to HRT
reported? Finally, clearness of the language used.
All the working groups worked independently, according
to self-defined explicit criteria, supported in their organi-
sation by the OC.
Population survey
A survey was carried out by the Istituto Superiore di Sanità
to seek information on women knowledge, attitudes and
behaviors about menopause and HRT. The survey
involved representative samples of women 45–60 years
from 5 Italian Regions, a total of 969 women were
selected from electoral rolls. Seven hundred twenty of
them (74,3% response rate) completed the interview car-
ried out by trained midwifes and social workers of mater-
nal and child health centers. The questionnaire
investigates women's experience in relation to menopause
(quality and prevalence of symptoms) hormone therapy
(use, indications, prescription and length of use) and
other treatments used; the type and amount of informa-
tion received about menopause, hormone therapy and
other possible treatments; finally, it gathers information
about personal habits, health status and socio-demo-
graphic characteristics [5].
Declaration of interest
In preparation of the CC, the OC made several efforts to
involve in the CC's process all interested parties and stake-
holders. An announcement was published in the Parteci-
pasalute and SNLG websites (http://
www.partecipasalute.it; http://snlg.it) and e-mails were
sent to medical societies, pharmaceutical companies,
patients' associations and other potentially relevant insti-
tutions. The announcement invited interested groups to
submit documents, comments or requests to participate at
the public final session of the CC. We collected thirty-
three declarations of interest in the conference and
twenty-eight documents were submitted to the OC. All the
documents collected were assigned to one of the three
working groups, according to the type of issue dealt with
(scientific articles or documents; information issues;
booklets targeted to women).
Conflict of interests
All members of the working groups, the scientific board
and the jury signed a declaration about their conflict of
interests.
Jury
The CC's jury was chaired by a lay member and was com-
posed of a member of the National agency for regional
healthcare services, two consumers' representatives, a
bioethicist, a jurist, two journalists, a gynaecologist, two
general practitioners, a clinical pharmacologist, an obste-
trician, a psychotherapist. The jury worked in complete
autonomy from the OC. It set its own procedural rules,
accepted by members 15 days before the public session as
a prerequisite to participate to the jury's work. The jury
had access to the documents produced by the working
groups one month before the public session of the CC.
During the public session in Turin, the jury listened to the
oral presentations of the working groups' data and then,
behind closed doors, it discussed the documents received
and defined the consensus statement. The preliminary
version of the consensus document was presented to the
public and the media. The writing committee, appointed
by the jury from within its members, completed the doc-
ument, without any substantive modifications of the con-
clusions agreed by the whole group. The final document
was approved by the jury one month after the two-day
open meeting.
Results
The CC's final document (see Additional file 1: Final
Report CC-HRT.pdf) was prepared taking into account all
the data and documentation produced by the three work-
ing groups and the discussion had during the two-day
open meeting in Torino. The document has been pro-
duced for the general public, medical and non-medical
experts interested in this issue or working in the area of
menopause and HRT. The jury used two different
approaches to communicate the main messages: 1) a con-
cise writing style to improve the clarity and dissemination
of the information; 2) a specialist and scientific style,
more accessible to medical professionals.
The jury considers the term "hormonal replacement ther-
apy" (HRT) as misleading since it may imply a situation of
hormonal deficiency and, consequently, a diseased state.Page 3 of 8
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the final document, the jury recommends instead the term
post-menopausal hormonal therapy (PHT) as more
appropriate. However, the term HRT has been used in the
document and the terminology has not been amended,
since the document answers to questions formulated and
defined with specific terms by the organising committee
and, consequently, not modifiable.
According with the questions of the consensus confer-
ence, the results fit in three major areas of interest: infor-
mation issues, clinical issues, and priorities for future
research.
Information issues
The data collected by the two working groups dealing with
information are summarised in table 2. They were evalu-
ated by the jury in order to answer the questions defined
by the OC, together with the population survey's results
reported elsewhere [5].
What is the information about menopause and HRT
that women would value most?
The information provided to women and to health oper-
ators should always be independent and evidence-based,
dealing with:
• the concept of menopause as part of the natural life
cycle;
• symptoms strictly related to the menopause, their
duration and the available treatments;
• risks and benefits of the treatments available (phar-
macological and alternative therapies);
• useful lifestyle changes.
Every woman should be able to exercise her right to take a
conscious and informed decision, after having access to
qualified sources of information able to provide definite
answers to questions related to menopause, therapies,
risks, uncertainties still present in research, and possible
non-pharmacological treatments.
What is the average quality of the information available
on this health issue? Which are the main risks for the
general public and for professionals associated with the
dissemination of deceitful and unreliable information?
How to improve the scientific quality of the informa-
tion?
The first articles published about HRT have initially high-
lighted its benefits. Subsequently these findings were
revised by studies published in the medical literature,
which have characterized the risks associated with the
treatment. The overall quality of the information about
menopause (from professional and non-professional
sources) is poor and it has clear methodological flaws,
contradictions and conflicts of interests (economic and
Table 2: Summary results of information working groups
Working groups dealing with information targeted to women (brochures, etc...)
Documents selected and reviewed: 78, most of them were published online
* 13 documents published by the national health system 
(NHS), 11 by scientific societies and 54 by private sources (pharmaceutical companies, publishing houses and patients associations)
* 68–87% of documents, particularly published online, were poorly written and had an inadequate graphical quality 
(13% reported tables or graphs and 32% illustrated with photos or images)
* less than 50% described menopause as a physiological phase of the life
* about 33% described the problems related to menopause as a disease
* about 75% of the pharmaceutical and specialised documents, and 50% of the documents produced by the NHS and scientific societies described 
HRT as a preventative measure; the main indication to HRT is the prevention of bone fractures
* 60–80% of the documents published by scientific societies, NHS, publishing houses, patients' associations, and in less than 50% of pharmaceutical 
and specialised documents reported the risks associated with HRT. Breast cancer is the mainly reported risk
* 50% of the documents were linked to commercial activities or sponsors, particularly herbal products
* 30–50% of documents did not report the original sources of information and 20% of the articles were written by an expert in the field
* 51% of the documents did not report information on sponsorship
Working group dealing with information published in mass media
Documents selected and reviewed: 225 articles
* 20 articles published in women magazines, 69 health magazines, 64 weekly news magazines, 32 newspapers, and 40 specialised journals
* most of the articles included pictures of women much younger than the HRT target Women
* 68% referred to the opinions of an expert in the field as the main sources of Information
* HRT is recommended to cure symptoms mainly in specialised journals (63%), and weekly news magazines (61%)
* 15% women magazines, 49% health magazines, 52% weekly news magazines, 38% newspapers and 68% specialised journals described HRT as a 
preventative measure
* 60% of the articles cited the risks of HRT
* the working group concluded that about half of the articles published in weekly news magazines and specialised periodicals, a fourth of the articles 
published in women's magazines and less than a third in health magazines might be helpful for women to make informed decisions
* the information on conflicts of interest is missing in 88% of the articlesPage 4 of 8
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formation is that women with non tolerated menopausal
symptoms would be prevented from having HRT even
though they could benefit from the treatment with rela-
tively modest risks. Therefore, it is critical to deliver scien-
tific and correct information on the current knowledge,
advantages and disadvantages, including areas of uncer-
tainties, pharmacological and non-pharmacological alter-
native treatments and their effectiveness.
The information should neither promote the use of HRT
nor raise concern about the use of HRT. Every therapeutic
decision should be based on an empathic patient-doctor
relationship to take into account the preferences and pri-
orities of every patient.
Clinical issues
Which characteristics of the menopause can be linked
to health problems?
Menopause is one of physiological phases in women's
life, which could sometimes affect their quality of life.
The medical problems with a proved association with
menopause are:
• vasomotor symptoms (sweating, flushing)
• vaginal dryness
• disturbed sleep.
Vasomotor symptoms and disturbed sleep are generally
short-lasting and variable in their intensity; however, they
may significantly affect women's quality of life. Other
medical conditions, frequently associated with meno-
pause (irritability, depression, osteoarticular pain, weight
gain) do not have a causal link with it, but they would
similarly require medical attention.
Why should we prescribe hormonal replacement ther-
apy (HRT), which are the main objectives of the ther-
apy, which women are eligible to receive it and what
would be the duration of the treatment?
Hormonal replacement therapy should be prescribed to
women with an early onset of the menopause, considered
as a pathological state, and to women with vasomotor
problems and disturbed sleep perceived as important and
persistent [7]. Vaginal dryness and difficult sexual inter-
course (dyspareunia) are not considered criteria for the
recommendation of systemic HRT and they can be treated
with topical treatments, which are generally effective.
However, women with milder symptoms may have a neg-
ative perception of the menopause and therefore they may
explicitly request HRT. The criteria for the prescription of
HRT in these cases cannot be defined and generalized and
the therapeutic plan for each patient should be individu-
ally discussed with a medical doctor.
Women should be informed that menopausal symptoms
may be short-lasting (with the exception of vaginal dry-
ness) and benign and they should be aware of the risks
and benefits associated with the use of HRT, of the fre-
quent recurrence of the symptoms after its interruption
and of the availability of non-pharmacological treatments
able to alleviate symptoms in order to make an informed
and conscious decision. Every woman should receive
updated and clear information on the available non-phar-
macological treatments and lifestyle modifications pro-
grams.
Clear evidence about the optimal duration of the treat-
ment to effectively control the symptoms is currently not
available. The approved clinical guidelines, which specifi-
cally suggest a short duration of the treatment and the pre-
scription of the lowest hormonal dose able to control
symptoms, should be followed.
Hormone replacement therapy, based on the current evi-
dence, is not recommended for the prevention of age-
related diseases as it carries a high risk/benefit ratio related
to:
• increased risk of breast cancer which is directly asso-
ciated with the duration of the treatment and possibly
with the type of estro-progestinic agent used [8];
• RCTs have not demonstrated the effectiveness of
HRT for the prevention of cardiovascular diseases, par-
ticularly for myocardial infarction, whereas there is
evidence for an age-independent increase of the inci-
dence of stroke and deep vein thrombosis (DVT) [9];
• with reference to osteoporotic fractures, a treatment
is usually not recommended for their prevention, even
if started several decades before the age they become
more frequent [10];
• the current evidence suggests that HRT may not have
a protective effect on the cognitive decline and on the
prevention of dementia.
Natural progesterone-like agents are associated with a
lower incidence of breast cancer.Page 5 of 8
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logical, need more information?
It is important that every woman is informed about the
availability of pharmacological (HRT) and non-pharma-
cological treatments.
Menopause could provide the chance to health profes-
sionals to recommend changes in lifestyle, which would
certainly have beneficial effects towards menopausal
symptoms. Two important lifestyle changes to be recom-
mended are the adoption of a healthy and balanced diet
and the increase in physical activity in order to reduce the
risk of osteoporosis, CVDs, obesity, urinary incontinence
and vasomotor symptoms.
The choice of the different non-pharmacological treat-
ments should be supported by educational and counsel-
ling sessions on the subject of menopause.
Priorities for future research
What are the priorities for research?
The jury identified several areas of uncertainties related to
HRT which could be investigated in RCTs. However, the
feasibility (samples size, resources, ethics) and the clinical
relevance of the results should be evaluated before design-
ing any new study. The most significant topic, related to
the information and therapeutic demands of women, is
the assessment of potential treatments able to control
menopausal symptoms and, in general, to improve the
quality of life. These studies may require smaller human
and financial resources (smaller samples size) and could
potentially provide useful clinical information to improve
women's quality of life during the menopause.
Discussion
The approach we used was effective in involving lay peo-
ple in the debate about HRT and the management of men-
opause. Particularly, the participation of consumers and
journalists in the two specific working groups gave the
jury the opportunity to be exposed to a wide range of
views through the documents produced. The presence of
consumers representatives and journalists in the jury rein-
forced this contribution: their involvement was particu-
larly significant considering the focus of the CC on the
information.
The jury stressed that menopause is not a disease but a
phase of life and, as such, does not require medical treat-
ment in itself. This seems in accordance with the attitude
of most of the women interviewed in the population sur-
vey carried out for this CC: more than 90% of the sample
believes that menopause is a normal phase in women's
life and almost half of the sample states it is a positive
experience for a woman. More than half of the sample did
not receive any information about menopause and possi-
ble remedies. Lack of knowledge was associated with low
educational level and absent or scarce access to health
services and prevention opportunities, like female cancer
screening. It has been demonstrated that women's atti-
tudes towards the menopause and their knowledge of the
benefits and risks of HRT have a direct effect on their use
of the therapy [11] and also that clinicians have a strong
influence on women's behavior towards HRT [11,12].
Other sources of information are the mass media, that
conveys to women messages often low quality and con-
flicting. This is true both for most of the documents avail-
able online, and for many of the articles published in lay
press. Some studies have found that women, not trusting
in the first opinion given by a medical expert, often have
used web based health services to seek a second opinion
about a problem related to menopause. This behaviour
has almost certainly been adopted by Italian women too,
nevertheless, the examination of the information availa-
ble on internet found that only about 20% of the pub-
lished material may be useful to make an informed
decision about treatments. The analysis suggests that the
information about menopause is often poor and not inde-
pendent. The lack of references of information in almost
half of the documents considered is a sign of scarce trans-
parency and does not allow the assessment of the reliabil-
ity of the content. More and better information should be
given to middle-aged women to improve their skill to
make informed choices regarding the use of HRT. To reach
this goal, the jury stressed the need to improve scientific
journalism in Italy. The following aspects should be the
priorities for such effort: a better and focused opportunity
for training; a better understanding of the complexities in
the interpretation of scientific issues and a more critical
approach against experts' views and statements. The
potential negative influence of conflicts of interests in the
validity and reliability of the information should be
appreciated; more attention is needed to avoid an unbal-
anced use of the information as propaganda. The availa-
bility of reliable documents produced by institutional
sources, with careful selection and description of the ref-
erences, could be helpful as reference to compare the
other sources of information. Similarly to what is already
suggested in the professional area, the general public
should use appropriate criteria to search for information
on internet in order to verify the quality and the inde-
pendence of the sources.
The jury recommends to prescribe HRT to women with an
early onset of the menopause and to women with vaso-
motor problems and disturbed sleep perceived as impor-
tant and persistent, not for prevention purposes. It
suggests a short duration of the treatment and the pre-Page 6 of 8
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indicated in the approved clinical guidelines. Areas of
uncertainties which could be investigated in properly
designed studies are identified by the jury. The most sig-
nificant topic is the assessment of potential treatments
able to control menopausal symptoms and to improve
quality of life. The analysis of the cost-effectiveness of
HRT's effects and observational epidemiological studies,
including assessment of behaviour, lifestyle, drugs and
alternative therapies, should also be promoted. The most
important RCTs have investigated conjugated estrogens,
which are scarcely available in Italy and Europe. Most of
the results from these studies cannot be generalised
because of the age and physical characteristics of women
enrolled in these trials (initial phase of menopause) and
supposed to take HRT. It would be appropriate to plan
studies to investigate the risks associated with the treat-
ments normally used in our daily practice and in women
routinely taking them to test their effectiveness and effi-
cacy. This research plan would require large financial and
human investments but it could potentially provide
important information on the safety (DVT, breast cancer),
which has not yet been investigated in other RCTs.
This experience has some limitations due to the method-
ology of the consensus conferences and to the process
required for the preparatory activities. The jury and the
three working groups were all appointed by the organising
committee according to criteria shared with the scientific
board. The working group on clinical issues did not
undertake a systematic review of the scientific literature
on HRT but appraised the guidelines – published by insti-
tutions and scientific societies – and systematic reviews
already available and some original articles considered
relevant by the group.
The OC disseminated the CC's final statement to reach a
wide target and increase the implementation of the
results. With this aim, the final recommendations of the
Jury have been briefly reported in the Bollettino d'infor-
mazione sui farmaci (BIF), the official journal of AIFA, the
Italian medicine agency [13].
The dissemination of the CC recommendations and their
impact will be evaluated through a project funded by a
grant of the Italian Ministry of Health. It will be carried
out in several Italian Regions in the next two years in order
to support women's decision making process about HRT,
and to evaluate the impact of the dissemination activities
on HRT prescriptions through a before- after research.
Conclusion
The consensus conference provides indications about the
priorities for information on hormone replacement ther-
apy.
The final document supports the use of hormone replace-
ment therapy in women at the beginning of menopause
and suffering for hard-to-bear symptoms or in early men-
opause; hormone replacement therapy should be used for
the shortest possible period and at the lowest effective
doses.
The consensus conference's final document recommends
that the term "post menopausal hormone therapy" substi-
tutes hormone replacement therapy, in order to avoid that
menopause is classified as a syndrome due to lack of hor-
mones.
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